The FY2025 (Dec) proxy of Assembly Biosciences names 18 peer companies for pay. Among Assembly Biosciences and these peers, CEO pay was 5th highest of 9 and total shareholder return was 2nd highest of 9.
5th highest of 9in Assembly Biosciences and its pay peers, FY2025 (Dec) by CEO pay:
$1.4M$4.7M
2nd highest of 9in Assembly Biosciences and its pay peers, FY2025 (Dec) by total shareholder return:
$9$266
Pay peer group, FY2025 (Dec) proxy
| CytomX Therapeutics | ||
| aTYR Pharma | ||
| Atea Pharmaceuticals | ||
| Enanta Pharmaceuticals | ||
| Gossamer Bio | ||
| Black Diamond Therapeutics | ||
| Spero Therapeutics | ||
| Arbutus Biopharma | ||
| AN2 Therapeutics, Inc. | Not disclosed | Not disclosed |
| Adverum Biotechnologies, Inc. | Not disclosed | Not disclosed |
| Aligos Therapeutics, Inc. | Not disclosed | Not disclosed |
| Caribou Biosciences | Not disclosed | Not disclosed |
| Hookipa Pharma Inc. | Not disclosed | Not disclosed |
| Invivyd | Not disclosed | Not disclosed |
| Kronos Bio, Inc. | Not disclosed | Not disclosed |
| Precision Biosciences, Inc. | Not disclosed | Not disclosed |
| Terns Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Vaxart, Inc. | Not disclosed | Not disclosed |
18 companies
Changes by year
FY2025 (Dec) proxy
- RemovedAnnexonpay peer group
- RemovedBolt Biotherapeutics, Inc.pay peer group
- RemovedOric Pharmaceuticalspay peer group
- RemovedOlema Pharmaceuticalspay peer group
- RemovedSpruce Biosciences, Inc.pay peer group
FY2024 (Dec) proxy
- RemovedAkero Therapeutics, Inc.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedAtara Biotherepeutics, Inc.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedConcert Pharmaceuticals, Inc.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedCymaBay Therapeutics, Inc.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedEiger BioPharmaceuticals, Inc.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedJounce Therapeutics, Inc.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedSangamo Therapeutics, Inc.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedViking Therapeuticspay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
- RemovedWave Live Sciences, Ltd.pay peer groupDue to the above criteria, several companies were either added to or removed from the peer group as a result of M&A activity, bankruptcy proceedings, out of scope market capitalization, headcount or stage of development. 89bio, Inc., Akero Therapeutics, Inc., Atara Biotherepeutics, Inc., Concert Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Jounce Therapeutics, Inc., Sangamo Therapeutics, Inc., Viking Therapeutics, Inc. and Wave Live Sciences, Ltd. were each members of our 2023 Peer Group
FY2023 (Dec) proxy
- RemovedCalithera Biosciences, Inc.pay peer groupdue to the new size parameters or because they were acquired
- RemovedEnanta Pharmaceuticalspay peer groupdue to the new size parameters or because they were acquired
- RemovedEpizyme, Inc.pay peer groupdue to the new size parameters or because they were acquired
- RemovedMadrigal Pharmaceuticalspay peer groupdue to the new size parameters or because they were acquired
- RemovedRegenxbiopay peer groupdue to the new size parameters or because they were acquired
- RemovedRhythm Pharmaceuticalspay peer groupdue to the new size parameters or because they were acquired
- RemovedSeres Therapeuticspay peer groupdue to the new size parameters or because they were acquired
- RemovedSpero Therapeuticspay peer groupdue to the new size parameters or because they were acquired
- RemovedSyros Pharmaceuticals, Inc.pay peer groupdue to the new size parameters or because they were acquired
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.